Advertisement

Chromatographia

, 70:1399 | Cite as

GC–MS Determination of Atenolol Plasma Concentration after Derivatization with N-methyl-N-(trimethylsilyl)trifluoroacetamide

  • Bilal YilmazEmail author
  • Sakir Arslan
Original

Abstract

An analytical procedure was developed and validated for the determination of atenolol in human plasma. Atenolol and metoprolol (internal standard) were extracted from human plasma with a mixture of chloroform and butanol at basic pH. The extracts were derivatized with N-methyl-N-(trimethylsilyl)trifluoroacetamide and analyzed by GC–MS. Calibration curves were linear over the concentration range 15–250 ng mL−1. Intra- and inter-day precision values for atenolol in human plasma were less than 7.4, and accuracy (relative error) was better than 6.4%. Recovery of atenolol from human plasma averaged 90.46%. The limits of detection (LOD) and quantitation (LOQ) of atenolol were 5.0 and 15 ng mL−1. This method was successfully applied to six patients with hypertension who had been given an oral tablet of 50 mg atenolol.

Keywords

Gas chromatography–mass spectrometry Atenolol in plasma Pharmacokinetics 

Notes

Acknowledgments

The authors would like to thank Abdi Ibrahim Pharmaceutical Industry for the atenolol standard and Tensinor tablet.

References

  1. 1.
    Al-Ghannam SM (2006) J Pharm Biomed Anal 40:151–156CrossRefGoogle Scholar
  2. 2.
    Pires de Abreu LR, Calafatti de Castro SA, Pedrazzoli J Jr (2003) AAPS PharmSci 5 (2): Article 21Google Scholar
  3. 3.
    Chatterjee DJ, Li WY, Hurst AK, Koda RT (1995) J Liq Chromatogr 18:791–806CrossRefGoogle Scholar
  4. 4.
    Giachetti C, Tencoti A, Canali S, Zanolo G (1997) J Chromatogr B 698:187–194CrossRefGoogle Scholar
  5. 5.
    Dale AD, Turner SE (1990) J Pharm Biomed Anal 8:1055–1058CrossRefGoogle Scholar
  6. 6.
    Miller RB (1991) J Pharm Biomed Anal 9:849–853CrossRefGoogle Scholar
  7. 7.
    Morris RG, Saccoia NC, Sallustio BC, Zacest R (1991) Ther Drug Monit 13:345–349CrossRefGoogle Scholar
  8. 8.
    Chiu FCK, Zhang JN, Li RC, Raymond K (1997) J Chromatogr B 691:473–477CrossRefGoogle Scholar
  9. 9.
    Li W, Li Y, Francisco DT, Naidong W (2005) Biomed Chromatogr 19:385–393CrossRefGoogle Scholar
  10. 10.
    Arias R, Jimenez RM, Alonso RM, Telez M, Arrieta I, Flores P, Ortiz-Lastra E (2001) J Chromatogr A 916:297–304CrossRefGoogle Scholar
  11. 11.
    Black SB, Stenhouse AM, Hansson RC (1996) J Chromatogr B 685:67–80CrossRefGoogle Scholar
  12. 12.
    Proceedings of the International Conference on Harmonization (ICH), Commission of the European Communities, 1996Google Scholar
  13. 13.
    Donike M (1969) J Chromatogr 42:103–104CrossRefGoogle Scholar
  14. 14.
    Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, 2001Google Scholar
  15. 15.
    Milena G, Ramirez G, Velasquez O, Perez M, Restrepo P (2005) ARS Pharm 46:411–427Google Scholar
  16. 16.
    Gibaldi M, Perrier D (1990) Pharmacokinetics, 2nd edn. Marcel Dekker, NYGoogle Scholar
  17. 17.
    Paik MJ, Lee J, Kim KR (2007) Anal Chim Acta 601:230–233CrossRefGoogle Scholar

Copyright information

© Vieweg+Teubner | GWV Fachverlage GmbH 2009

Authors and Affiliations

  1. 1.Department of Analytical Chemistry, Faculty of PharmacyAtaturk UniversityErzurumTurkey
  2. 2.Department of Cardiology, Faculty of MedicineAtaturk UniversityErzurumTurkey

Personalised recommendations